m⁴ Projects

PM28; In the m4 project of GeneWake, a blood or urine test will be developed, which allows early detection and therapy monitoring of prostate and bladder cancer.

Genomatix Software GmbH

Development of Integrated Prognostic, Diagnostic, and Therapeutic Approaches in Personalized Medicine by Integral Network Analysis

PM13; regulatory networks, biomarker, genome-sequencing, high-throughput analysis, theragnostics

Intana Bioscience GmbH

Improvement of Effectiveness and Specificity of RNAi for Research and Therapeutics by Modified Effector Proteins of the Argonaute Familiy

T18; genomics, cell based screening, gene silencing, RNA-protein interaction, single molecule detection

itg GmbH

Klinikum der Universität München (LMU)

Development of cyclic peptides for diagnostics and therapy in oncology

PM9; cancer, imaging, therapeutic and diagnostic radio isotopes

Klinikum der Universität München

Novartis Pharma GmbH

Max-Planck-Institut für Psychiatrie

Network of Excellence for Neuroendocrine Tumors Munich (NeoExNETM)

PM1; cancer, platform for pre-clinical and clinical studies, biobanking

Klinikum rechts der Isar of TU Munich
Roche Pharma AG

Anti KIR4.1 autoantibodies as biomarker for therapy decisions in multiple sclerosis

PM23; multiple sclerosis, early diagnosis, prevention

Klinikum der Universität München (LMU)

Siemens Healthcare

Non-Invasive Monitoring of molecular therapies in oncology

PM7; perfusion imaging, therapy response, biomarker, oncology, clinical translation

Klinikum rechts der Isar der TU München

Helmholtz Zentrum München

Philips Medizinsysteme

Development and Evaluation of New CT- and MRI-Techniques for Evaluation of Pharmaceutical Treatment Response

PM8; cancer, inflammation, imaging, pre-clinic

Klinkum rechts der Isar der TU München

Johann-Wolfgang-Goethe-Universität Frankfurt

Friedrich-Alexander-Universität Erlangen-Nürnberg

Determination of immune and tumor parameters in serum of tumor patients

PM6; serum markers, prognostic markers, test kit development, immune matrix, anti-tumor immunity, therapy monitoring, Hsp70 protein, HMGB1, AnnexinA5, Survivin

Ludwig-Maximilians-Universität München

Qualification and Operation of the Sterile Facility in the Department of Pharmacy, LMU Munich

P3; biopharmaceuticals, clinical trial, sterile dosage form, personalized medicine, manufacturing

Ludwig-Maximilians-Universität München

Roche Kulmbach GmbH

siRNA as new therapeutic platform

T12; precise polymers, nanoparticles, drug targeting, stabilization, tumor therapy

MorphoSys AG

Klinkum rechts der Isar der TU München

MOR202, a Novel Targeted Therapy for the Treatment of Multiple Myeloma

T4; Monoclonal, antibody, plasma cell, biomarker, CD38

MorphoSys AG

Proteros biostructures GmbH

Structure-based characterization of therapeutic antibodies

T17; X-ray crystallography, protein structure, antibody-antigen-structure, therapeutic antibodies, drug discovery

Minitüb GmbH

Genzentrum der Ludwig-Maximilians-Universität München

Technische Universität München

Platform „Advanced Preclinical Animal Models“

PK1; Diabetes, Immunschwäche, Krebs, Zelltherapie, Präklinik

Origenis GmbH

Development of biomarkers for the preclinical diagnostic of humane neuro-degenerative diseases modulated by Leucine-rich repeat kinase 2 (LRRK2)

PM21; small molecules, targeted therapy, neuro-degeneration, molecular imaging

Paktis GmbH

Genzentrum der Ludwig-Maximilians-Universität München

Klinikum rechts der Isar der TU München

Transgenic Livestock Platform for Production of Recombinant Antibodies for Therapeutic Applications

P2; prostate cancer, therapeutic antibody, pre-clinical

Pieris AG
DKFZ Heidelberg
University of Torino

Pre-clinical Development of RPRS-110, an anticalin directed against c-Met in oncology

PM 18; cancer, anticalin, targeted therapy

Priaxon AG

Technische Universität München

Tailored Inhibitors against Essential Bacterial Virulence Factors

T9; anti-infectives, antibiotic resistance, immune evasion, chronic infection, nosocomial infection

SpheroTec GmbH
Klinikum der Universität München (LMU)
Klinkum rechts der Isar der TU München

Individualisation of cancer therapy combining biomarker profiling and functional drug screening in the Spheroid Microtumor Model

PM2; cancer, biomarker profile, tumor resistance, drug discover

SuppreMol GmbH
University Regensburg

Devolopment of a IL-3 specific antibody

PM19; Autoimmune Erkrankung, Entzündliche Erkrankungen, therapeutische Proteine, Präklinik

SuppreMol GmbH
Max-Planck-Institut für Neurobiologie
Friedrich-Alexander-Universität Erlangen
Klinikum der Universität München (LMU)

Fc-Receptors as Targets for the Therapy of Autoimmune Diseases

T5; inflammation, autoimmune disease, therapeutic protein, clinical study

Technische Universität München

Stage Cell Therapeutics GmbH

Reversible Streptamer Reagents

PM14; cell isolation, clinical trial, surface marker, GMP, minimally manipulated cells

Technische Universität München
Klinikum der Universität München (LMU)
Qualimed Innovative Medizinprodukte GmbH

MicroRNA-based therapy for cardiac disease

T6; cardiovascular disease, pre-clinic

TRION Research GmbH

Klinkum rechts der Isar der TU München

Klinikum Köln-Merheim/Universität Witten Herdecke

Klinikum der Universität München (LMU)

Immunomonitoring in context of “investigator-initiated trials“ with the Triomab® antibodies FBTA05 and catumaxomab

PM4; trifunctional antibodies, anti-tumor response, peritoneal carcinomatosis, B cell malignancies, cytotoxic T cells

Wilex AG
Klinkum rechts der Isar der TU München

Preclinical and clinical development of a PI3 Kinase Inhibitor for the treatment of tumors

T3; cancer, patient trial, small molecules

XL-protein GmbH

Technische Universität München

PASylation®: Superior biopharmaceuticals with extended plasma half-life

T15; amino acid polymer, antibody fragment, blood circulation time, Exendin-4, GLP-1 agonist, hGH, peptide, random coil, therapeutic protein